Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Acute Coronary Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to' returned 6 results - Page 1 of 1   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Emerging Medical Technologies Spotlight, a Report of Investment & Partnering Opportunities 2010   Life Science Intelligence, Inc., Jan 2011 (PICSO) device for acute coronary syndrome (ACS) and heart failure patients - Ophthalmic formulation of mitomycin-C in a single-use kit, for use in the surgical treatment of glaucoma - Molecular Molecular Diagnostics - Technologies, Markets and Companies   Jain PharmaBiotech, May 2012, Pages: 1037 technologies, applications and geographical regions. Forecasts are made up to 2021. A major portion of the molecular diagnostic market can be attributed to advances in genomics and proteomics. Biochip and Cardiac Biomarkers - Global Strategic Business Report   Global Industry Analysts, Inc., Oct 2011, Pages: 444 prevention of conditions, such as coronary thrombosis and stroke. Besides, these biomarkers are capable of accurately assessing risks of Acute Coronary Syndrome (ACS), stroke and other cardiovascular events in Emerging Medical Technologies Spotlight, a Report of Investment & Partnering Opportunities 2009   Life Science Intelligence, Inc., Dec 2009, Pages: 1763 acute myocardial infarction - Technology for diagnosing breast and ovarian cancers and determining responsiveness to new therapeutics - Polymer-based/biodegradable/drug-eluting peripheral vascular stent Neuroprotection - Drugs, Markets and Companies   Jain PharmaBiotech, May 2012, Pages: 633 known to have a neuroprotective effect. With the approval of new products and takeover of markets for obsolete symptomatic therapies, the neuroprotection market value will rise by the year 2016 when it Emerging Medical Technologies (EMT) Database   Life Science Intelligence, Inc., July 2007 - Magnesium-based compound that will attach bone to bone and ligaments and tendons to bone Company 53 - Cath lab solution providing rapid onset of circulatory support in patients with acute heart failure Results:  First -   Prev -   1 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets2    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network